Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation

被引:33
作者
Guikema, JEJ
Vellenga, E
Veeneman, JM
Hovenga, S
Bakkus, MHC
Klip, H
Bos, NA
机构
[1] Univ Groningen Hosp, Dept Haematol, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen, Fac Med, Dept Histol & Cell Biol, Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Clin Chem, NL-9713 GZ Groningen, Netherlands
[4] Free Univ Brussels, Fac Med, Dept Haematol & Immunol, Brussels, Belgium
关键词
multiple myeloma; autologous stem cell transplantation; myeloma clonally related cells; ASO-RT-PCR;
D O I
10.1046/j.1365-2141.1999.01233.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A high incidence of oligoclonal serum M-components is observed in multiple myeloma (MM) patients treated with autologous Stem cell transplantation (ASCT). To determine whether these hi-components are produced by myeloma clonally related cells or caused by an aberrant B-cell regeneration we analysed by semi-nested ASO-RT-PCR and DNA sequencing the immunoglobulin (Ig) variable genes (VH) obtained from bone marrow samples obtained before and after transplantation and peripheral blood stern cell (PBSC) samples from seven patients. Myeloma clonally related cells are identifiable by the expression of variant Ig heavy chain isotypes and were detected in two patients at presentation. No myeloma clonally related cells were found in post-transplantation samples (n = 7) in spite of the appearance of new serum M-components, However, in two cases we amplified sequences from post-transplantation bone marrow cells that were able to bind to the B-cell clone-specific CDR3 oligonucleotides but showed no further similarity regarding the VDT rearrangement, These data indicate that serum oligoclonality posttransplantation is not caused by myeloma clonally related B cells but rather by the regenerating B-cell compartment.
引用
收藏
页码:748 / 754
页数:7
相关论文
共 13 条
[1]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[2]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031
[3]   THE HUMAN-IMMUNOGLOBULIN V-H REPERTOIRE [J].
COOK, GP ;
TOMLINSON, IM .
IMMUNOLOGY TODAY, 1995, 16 (05) :237-242
[4]   EVIDENCE FOR A BONE-MARROW B-CELL TRANSCRIBING MALIGNANT PLASMA-CELL VDJ JOINED TO C-MU SEQUENCE IN IMMUNOGLOBULIN (IGG)-SECRETING AND IGA-SECRETING MULTIPLE MYELOMAS [J].
CORRADINI, P ;
BOCCADORO, M ;
VOENA, C ;
PILERI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1091-1096
[5]  
DURIE BGM, 1986, SEMIN ONCOL, V13, P300
[6]   PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BLADE, J ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRATWOHL, A ;
HAGENBEEK, A ;
JACOBS, P ;
DELAURENZI, A ;
VANLINT, M ;
MICHALLET, M ;
NIKOSKELAINEN, J ;
REIFFERS, J ;
SAMSON, D ;
VERDONCK, L ;
DEWITTE, T ;
VOLIN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1312-1322
[7]  
GERRITSEN EJA, 1993, BLOOD, V82, P3493
[8]  
Glas AM, 1995, ANN NY ACAD SCI, V764, P312
[9]  
HAROUSSEAU JL, 1992, BLOOD, V79, P2827
[10]  
PASCALI E, 1982, CLIN CHEM, V28, P1404